Form 8-K - Current report:
SEC Accession No. 0001398733-25-000022
Filing Date
2025-10-08
Accepted
2025-10-08 07:23:31
Documents
17
Period of Report
2025-10-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20251008.htm   iXBRL 8-K 26883
2 EX-99.1 iprelease10-6x25.htm EX-99.1 13608
6 iprelease10-6x25001.jpg GRAPHIC 234846
7 iprelease10-6x25002.jpg GRAPHIC 265271
8 iprelease10-6x25003.jpg GRAPHIC 305718
9 iprelease10-6x25004.jpg GRAPHIC 157735
  Complete submission text file 0001398733-25-000022.txt   1488480

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20251008.xsd EX-101.SCH 1776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20251008_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20251008_pre.xml EX-101.PRE 12504
19 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20251008_htm.xml XML 2719
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 251381231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)